

**Regd. Office and works:**

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231  
Pithampur - 454775, Dist. Dhar  
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com)Website:- [www.medicaps.com](http://www.medicaps.com)

MCL/SE/2023-24

Date: 08<sup>th</sup> November, 2023Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)

To,

**The General Manager**

DCS-CRD

**BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street Fort, Mumbai – 400001 (M.H.)

**SUBJECT: SUBMISSION OF THE STANDALONE AND CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED ON 30<sup>TH</sup> SEPTEMBER, 2023 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS, 2015.**

**REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)**

Dear Sir/Madam,

This is in continuation of our letter no. MCL/BM/SE/2023-2024 dated 01<sup>st</sup> November, 2023 regarding information of Board Meeting for consideration and approval of Standalone as well as Consolidated Un-Audited Financial Results for the Quarter/Half Year ended on 30<sup>th</sup> September, 2023.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the un-audited Standalone and Consolidated Financial Results for the quarter as well as half year ended 30<sup>th</sup> September, 2023 duly approved by the Board at its meeting held today i.e. 08<sup>th</sup> November, 2023 along with Limited Review Report given by the Statutory Auditors of the Company, as required under the above said Regulations.

Further, pursuant to Regulation 33(3)(f) and (g) of the SEBI Listing Regulations, we have also enclosed Statements of Assets and Liabilities and the Statement of Cash flow in the prescribed format for the half year ended 30<sup>th</sup> September, 2023.

Further, above Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid results shall also be uploaded on the Company's website at [www.medicaps.com](http://www.medicaps.com) and on the website of the Stock Exchange at [www.bseindia.com](http://www.bseindia.com). Further, the extract of aforesaid results shall also be published in one Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Financial Results for your records and reference.

Thanking You,

Yours Faithfully,

**FOR MEDI-CAPS LIMITED**

**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**

*Enclosed: Unaudited Standalone and Consolidated Financial Results along with limited review report for quarter and half year ended 30<sup>th</sup> September, 2023*

# RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com., cprawka@gmail.com

## Independent Auditor's Review Report On Standalone Unaudited Quarterly and half year ended Financial Results of Medi-Caps Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors of  
**MEDI-CAPS LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of MEDI-CAPS LIMITED ("the Company") for the quarter and half year ended 30<sup>th</sup> September, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, Interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results, prepared in accordance with the aforesaid Indian Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Our conclusion on the Statement is not modified in respect of the above matter.

Place: Indore

Date: 08/11/2023

UDIN: 23429040BGXBJW5477

For: Rawka & Associates  
(Chartered Accountants)



A handwritten signature in black ink, appearing to read 'Venus Rawka', written over a white background.

Venus Rawka  
(Partner)

M. No. 429040

FRN: 021606C

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30.09.2023**


		Amount in Laes except EPS					
S.N.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sept 30th, 2023	June 30th, 2023	Sept 30th, 2022	Sept 30th, 2023	Sept 30th, 2022	March 31st, 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I</b>	<b>Revenue from Operation</b>						
	(a) Net sales	210.64	0.00	0.00	210.64	0.00	0.00
	(b) Other operating income	2.46	1.77	1.29	4.23	2.65	10.14
	<b>Revenue from Operation</b>	<b>213.10</b>	<b>1.77</b>	<b>1.29</b>	<b>214.87</b>	<b>2.65</b>	<b>10.14</b>
<b>II</b>	<b>Other Income</b>	0.00	0.80	60.52	0.80	61.78	64.46
<b>III</b>	<b>Total income (I+II)</b>	<b>213.10</b>	<b>2.57</b>	<b>61.81</b>	<b>215.67</b>	<b>64.43</b>	<b>74.60</b>
<b>IV</b>	<b>Expenses</b>						
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.34	0.00	0.00	0.34	0.00	0.00
	d) Employee benefits expense	5.65	6.10	6.11	11.75	11.52	23.27
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	4.00	4.00	2.30	8.01	4.61	9.23
	g) Power Cost	0.11	0.06	0.00	0.17	0.00	0.21
	h) Freight Exp.	0.00	0.00	0.00	0.00	0.00	0.00
	i) Other expenses	9.77	30.63	3.07	40.40	9.65	16.32
	<b>Total Expenses (IV)</b>	<b>19.87</b>	<b>40.79</b>	<b>11.50</b>	<b>60.67</b>	<b>25.79</b>	<b>49.03</b>
<b>V</b>	<b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>	<b>193.23</b>	<b>-38.22</b>	<b>50.31</b>	<b>155.00</b>	<b>38.64</b>	<b>25.57</b>
<b>VI</b>	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>VII</b>	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>193.23</b>	<b>-38.22</b>	<b>50.31</b>	<b>155.00</b>	<b>38.64</b>	<b>25.57</b>
<b>VIII</b>	<b>Tax expense</b>						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	0.00
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-0.14
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>-0.14</b>
<b>IX</b>	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
<b>X</b>	Profit (Loss) for the period from continuing operations (VII-VIII)	193.23	-38.22	50.31	155.00	38.64	25.71
<b>XI</b>	Profit/(loss) from discontinued operations	0.00	0.00	-1.42	0.00	-5.73	-11.07
<b>XII</b>	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>XIII</b>	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	0.00	-1.42	0.00	-5.73	-11.07
<b>XIV</b>	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
<b>XV</b>	Profit/(loss) for the period (X+XIII)	193.23	-38.22	48.90	155.00	32.92	14.64
<b>XVI</b>	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	39.71	30.22	-26.09	69.93	-50.57	-32.70
	(ii) Income tax on items that will not to be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P&L	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other comprehensive income :</b>	<b>39.71</b>	<b>30.22</b>	<b>-26.09</b>	<b>69.93</b>	<b>-50.57</b>	<b>-32.70</b>
<b>XVII</b>	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	232.94	-8.00	22.81	224.93	-17.65	-18.06
<b>XVIII</b>	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00

<b>XIX</b>	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>XX</b>	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
<b>XXI</b>	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	0.00	4863.75
<b>XXII</b>	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	1.55	-0.31	0.40	1.24	0.31	0.21
	b) Diluted (Rs.)	1.55	-0.31	0.40	1.24	0.31	0.21
	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	-0.01	0.00	-0.05	-0.09
	b) Diluted (Rs.)	0.00	0.00	-0.01	0.00	-0.05	-0.09
	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	1.55	-0.31	0.40	1.24	0.26	0.12
	b) Diluted (Rs.)	1.55	-0.31	0.40	1.24	0.26	0.12

DATE: 08.11.2023

PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED



**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231


**UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2023**

The standalone Statement of Assets & Liabilities is as under:		(Amount in Lacs)	
		Standalone	
Particulars	As at		
	30-09-2023	31-03-2023	
	Unaudited	Audited	
<b>I. Assets</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipment	234.12	246.49	
(b) Capital work-in-progress	0.00	0.00	
(c) Goodwill	0.00	0.00	
(c) Investment Property	0.00	0.00	
(d) Financial Assets			
(i) Investments	4390.67	4390.67	
(e) Other non-current assets	4.91	4.91	
<b>Sub Total - Non-Current Assets</b>	<b>4629.70</b>	<b>4642.07</b>	
<b>(2) Current assets</b>			
(a) Inventories	4.03	0.00	
(b) Financial Assets			
(i) Investments	897.63	806.90	
(ii) Trade receivables	367.04	223.82	
(iii). Cash and cash equivalents	7.59	4.05	
(iv) Bank balances other than (iii) above	0.00	0.00	
(c) Other current assets	485.29	485.70	
<b>Sub Total - Current Assets</b>	<b>1761.58</b>	<b>1520.47</b>	
<b>Total Assets</b>	<b>6391.28</b>	<b>6162.54</b>	
<b>II. EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity Share Capital	1247.00	1247.00	
(b) Other Equity	5088.70	4863.75	
<b>Sub Total - Equity</b>	<b>6335.70</b>	<b>6110.75</b>	
<b>LIABILITIES</b>			
<b>(1) Non-Current Liabilities</b>			
(a) Financial Liabilities	0.00	0.00	
(b) Provisions	0.00	0.00	
(c) Deferred tax liabilities (Net)	43.98	43.98	
<b>Sub Total - Non-Current Liabilities</b>	<b>43.98</b>	<b>43.98</b>	
<b>(2) Current Liabilities</b>			
(a) Financial Liabilities	0.00	0.00	
(i) Borrowings	0.00	0.00	
(ii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises; and			
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	0.00	0.00	
(iii) Other financial liabilities (other than those specified in item (b) ),	0.00	0.00	
(b) Other current liabilities	11.60	7.81	
(c) Provisions	0.00	0.00	
(d) Current Tax Liabilities (Net)	0.00	0.00	
<b>Sub Total - Current Liabilities</b>	<b>11.60</b>	<b>7.81</b>	
<b>Total Equity and Liabilities</b>	<b>6391.28</b>	<b>6162.54</b>	

DATE: 08.11.2023

PLACE: INDORE

For and on behalf of board of directors of  
**MEDI-CAPS LIMITED**

  
**ALOK K.GARG**  
MANAGING DIRECTOR  
DIN: 00274321

## MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

### UNAUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30.09.2023

(Amount in Lacs)		
PARTICULARS	For the Half Year Ended 30th Sept 2023	For the Half Year Ended 30th Sept 2022
	Unaudited	Unaudited
A. Cash Flow from Operating Activities		
Net Profit/(Loss) before Tax & Extraordinary Items	155.00	38.64
Adjustment For:		
Depreciation	8.01	9.09
Dividend Income	0.00	0.00
Other Comprehensive Income	69.93	-50.57
Profit/(Loss) from Discontinue Operation	0.00	-5.73
Operating Profit before Working Capital Change	232.94	-8.56
Adjustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	-143.21	0.49
(Increase)/ Decrease in Inventories	-4.03	0.00
(Increase)/ Decrease in Loans & Advances	0.39	(206.91)
Increase in Current Liabilities & Provisions	3.79	0.06
Cash Generated from Working Capital	(143.06)	(206.36)
Cash generated from Operation	89.88	(214.92)
Net Income Tax Paid	0.00	0.00
Net cash Flow from Operating Activity	89.88	(214.92)
B. Cash Flow from Investing Activities		
Proceed from Sale/purchase of Fixed Assets	4.37	123.72
Purchase/Sale of Investment	(90.72)	15.00
Dividend Received	0.00	0.00
Net Cash used in Investing Activities	(86.35)	138.72
C. Cash Flow from Financial Activities		
Increase in Long term borrowing	0.00	0.00
Net Cash Used in Financial Activities	0.00	0.00
Net Increase in Cash and Cash Equivalents (A+B+C)	3.53	(76.20)
Cash & Cash Equivalents at the		
Beginning of the year	4.06	78.67
Closing of the year	7.59	2.47
Increase in Cash and Cash Equivalents	3.53	(76.20)

DATE: 08.11.2023

PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED

  
**ALOK K GARG**  
 MANAGING DIRECTOR  
 DIN: 00274321

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly and half year ended Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors of  
Medi-Caps Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Medi-Caps Limited ("the parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiary for the quarter and half year ended 30/09/2023 and for the period from 01/07/2023 to 30/09/2023, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its subsidiary Medgel Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of its subsidiary, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.



7. The consolidated unaudited financial results includes the interim financial results of Medgel Private Limited (subsidiary) which also has been reviewed by us and certified by the management whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs. 602.89 Lakhs, total net profit/(loss) after tax of Rs. 11.61 Lakhs and total comprehensive income of Rs. 130.04 Lakhs for the quarter ended 30/09/2023, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: Indore

Date: 08/11/2023

UDIN: 23429040BGXBJV9236

**For: Rawka & Associates**  
Chartered Accountants



A handwritten signature in blue ink, appearing to be "Venus Rawka", written over a horizontal line.

**Venus Rawka**  
(Partner)  
M.No. 429040  
FRN: 021606C



## MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30.09.2023**

		(Amount in Laacs except EPS)					
S.N.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sept 30th, 2023	June 30th, 2023	Sept 30th, 2022	Sept 30th, 2023	Sept 30th, 2022	March 31st, 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I</b>	<b>Revenue from Operation</b>						
	(a) Net sales	598.50	623.64	1528.81	1222.14	2746.05	4857.75
	(b) Other operating income	4.38	14.06	8.49	18.44	30.29	79.35
	<b>Revenue from Operation</b>	<b>602.88</b>	<b>637.70</b>	<b>1537.29</b>	<b>1240.57</b>	<b>2776.34</b>	<b>4937.10</b>
<b>II</b>	<b>Other Income</b>	7.40	6.75	89.84	14.15	119.56	160.32
<b>III</b>	<b>Total income (I+II)</b>	<b>610.28</b>	<b>644.45</b>	<b>1627.13</b>	<b>1254.72</b>	<b>2895.91</b>	<b>5097.42</b>
<b>IV</b>	<b>Expenses</b>						
	a) Cost of material consumed	126.31	270.04	765.43	396.35	1309.20	2205.25
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	47.38	23.73	3.03	71.10	72.60	85.21
	d) Employee benefits expense	173.15	179.33	189.50	352.48	357.12	768.92
	e) Finance costs	0.00	0.00	0.01	0.00	0.13	0.16
	f) Depreciation and amortisation expense	45.27	45.27	51.75	90.55	102.00	174.32
	g) Power Cost	40.28	37.91	72.94	78.20	117.87	216.22
	h) Freight Exp.	22.98	13.90	158.86	36.88	327.43	505.30
	i) Other expenses	143.30	185.72	169.93	329.02	330.69	649.97
	<b>Total Expenses (IV)</b>	<b>598.67</b>	<b>755.90</b>	<b>1411.45</b>	<b>1354.58</b>	<b>2617.04</b>	<b>4605.35</b>
<b>V</b>	<b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>	<b>11.61</b>	<b>-111.45</b>	<b>215.67</b>	<b>-99.86</b>	<b>278.86</b>	<b>492.07</b>
<b>VI</b>	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>VII</b>	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>11.61</b>	<b>-111.45</b>	<b>215.67</b>	<b>-99.86</b>	<b>278.86</b>	<b>492.07</b>
<b>VIII</b>	Tax expense						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	122.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	183.58
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-0.14
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>305.44</b>
<b>IX</b>	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
<b>X</b>	Profit (Loss) for the period from continuing operations (VII-VIII)	11.61	-111.45	215.67	-99.86	278.86	186.63
<b>XI</b>	Profit/(loss) from discontinued operations	0.00	0.00	-1.42	0.00	-5.73	-11.07
<b>XII</b>	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>XIII</b>	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	0.00	0.00	-1.42	0.00	-5.73	-11.07
<b>XIV</b>	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XV</b>	<b>Profit/(loss) for the period (X+XIII)</b>	<b>11.61</b>	<b>-111.45</b>	<b>214.26</b>	<b>-99.86</b>	<b>273.14</b>	<b>175.56</b>
<b>XVI</b>	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	118.43	109.82	25.92	228.25	-21.38	55.95
	(ii) Income tax on items that will not be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other comprehensive income :</b>	<b>118.43</b>	<b>109.82</b>	<b>25.92</b>	<b>228.25</b>	<b>-21.38</b>	<b>55.95</b>
<b>XVII</b>	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>130.02</b>	<b>-1.63</b>	<b>240.19</b>	<b>128.39</b>	<b>251.78</b>	<b>231.51</b>
<b>XVIII</b>	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	11.58	-111.45	214.26	-99.86	273.14	175.56
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00

<b>XIX</b>	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	130.02	-1.63	240.19	128.39	251.78	231.51
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
<b>XX</b>	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
<b>XXI</b>	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	0.00	10610.14
<b>XXII</b>	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	0.09	-0.89	1.73	-0.80	2.24	1.50
	b) Diluted (Rs.)	0.09	-0.89	1.73	-0.80	2.24	1.50
	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	-0.01	0.00	-0.05	-0.09
	b) Diluted (Rs.)	0.00	0.00	-0.01	0.00	-0.05	-0.09
	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	0.09	-0.89	1.73	-0.80	2.20	1.41
	b) Diluted (Rs.)	0.09	-0.89	1.73	-0.80	2.20	1.41

DATE: 08.11.2023

PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED



**ANIL K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435


Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2023**

The standalone and Consolidated Statement of Assets & Liabilities is as under:		(Amount in Lacs)	
Particulars	Consolidated		
	As at		
	30-09-2023	31-03-2023	
	Unaudited	Audited	
<b>I. Assets</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipment	3012.44		3076.73
(b) Capital work-in-progress	0.00		0.00
(c) Goodwill	2814.15		2814.15
(c) Investment Property	0.00		0.00
(d) Financial Assets			
(i) Investments	810.26		648.73
(e) Other non-current assets	38.61		38.58
<b>Sub Total - Non-Current Assets</b>	<b>6675.46</b>		<b>6578.19</b>
<b>(2) Current assets</b>			
(a) Inventories	725.98		706.90
(b) Financial Assets			
(i) Investments	2732.78		2558.70
(ii) Trade receivables	1014.92		846.44
(iii) Cash and cash equivalents	16.14		111.36
(iv) Bank balances other than (iii) above	0.00		0.00
(c) Other current assets	1401.64		1797.05
<b>Sub Total - Current Assets</b>	<b>5891.46</b>		<b>6020.45</b>
<b>Total Assets</b>	<b>12566.92</b>		<b>12598.64</b>
<b>II. EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity Share Capital	1247.00		1247.00
(b) Other Equity	10738.54		10610.14
<b>Sub Total - Equity</b>	<b>11985.54</b>		<b>11857.14</b>
<b>LIABILITIES</b>			
<b>(1) Non-Current Liabilities</b>			
(a) Financial Liabilities	0.00		0.00
(b) Provisions	57.85		58.87
(c) Deferred tax liabilities (Net)	43.98		43.98
<b>Sub Total - Non-Current Liabilities</b>	<b>101.83</b>		<b>102.86</b>
<b>(2) Current Liabilities</b>			
(a) Financial Liabilities	0.00		0.00
(i) Borrowings	0.00		0.00
(ii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises; and			
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	128.63		282.94
(iii) Other financial liabilities (other than those specified in item (b)),	0.00		0.00
(b) Other current liabilities	228.92		233.71
(c) Provisions			
(d) Current Tax Liabilities (Net)	122.00		122.00
<b>Sub Total - Current Liabilities</b>	<b>479.55</b>		<b>638.66</b>
<b>Total Equity and Liabilities</b>	<b>12566.92</b>		<b>12598.64</b>

DATE: 08.11.2023  
PLACE: INDORE

For and on behalf of board of directors of  
**MEDI-CAPS LIMITED**



**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

## MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231


### UNAUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30.09.2023

(Amount in Lacs)		
PARTICULARS	For the Half Year Ended 30th Sept 2023	For the Half Year Ended 30th Sept 2022
	Unaudited	Unaudited
<b>A. Cash Flow from Operating Activities</b>		
Net Profit/(Loss) before Tax & Extraordinary Items	-99.86	278.85
Adjustment For:		
Depreciation	90.55	106.48
Dividend Income	(0.33)	0.00
Other Comprehensive Income	228.25	-21.38
Profit/(Loss) from Discontinue Operation	0.00	-5.73
<b>Operating Profit before Working Capital Change</b>	<b>218.60</b>	<b>358.23</b>
Adjustment for Working Capital	0.00	
(Increase)/ Decrease in Sundry Debtors	-168.48	18.65
(Increase)/ Decrease in Inventories	-19.09	369.19
(Increase)/ Decrease in Loans & Advances	395.41	(1034.52)
Increase in Current Liabilities & Provisions	(160.13)	-390.09
<b>Cash Generated from Working Capital</b>	<b>47.72</b>	<b>(1036.76)</b>
<b>Cash generated from Operation</b>	<b>266.32</b>	<b>-678.53</b>
Net Income Tax Paid	0.00	0.00
<b>Net cash Flow from Operating Activity</b>	<b>266.32</b>	<b>-678.53</b>
<b>B. Cash Flow from Investing Activities</b>		
Proceed from Sale/purchase of Fixed Assets	(26.25)	(74.58)
Purchase/Sale of Investment	(335.62)	(89.27)
Dividend Received	0.33	0.00
<b>Net Cash used in Investing Activities</b>	<b>(361.54)</b>	<b>(163.85)</b>
<b>C. Cash Flow from Financial Activities</b>		
Increase in Long term borrowing	0.00	0.00
<b>Net Cash Used in Financial Activities</b>	<b>0.00</b>	<b>0.00</b>
<b>Net increase in Cash and Cash Equivalents (A+B+C)</b>	<b>(95.22)</b>	<b>(842.38)</b>
Cash & Cash Equivalents at the		
Beginning of the year	111.36	975.49
Closing of the year	16.14	133.11
<b>Increase in Cash and Cash Equivalents</b>	<b>(95.22)</b>	<b>(842.38)</b>

DATE: 08.11.2023

PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED

  
**ATOK K GARG**  
 MANAGING DIRECTOR  
 DIN: 00274321

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE QUARTER/HALF YEAR ENDED 30.09.2023**

		(Amount in Lacs)					
S.No.	Segment Revenue	Quarter Ended			Half Year Ended		Year Ended
		Sept 30th, 2023	June 30th, 2023	Sept 30th, 2022	Sept 30th, 2023	Sept 30th, 2022	March 31st 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Segment Revenue</b>						
	Pharma Division	397.18	641.89	1565.32	1039.04	2831.48	5022.83
	Real Estate Division	213.10	2.57	61.81	215.67	64.43	74.60
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Net Sale/Income From Operations</b>	<b>610.28</b>	<b>644.45</b>	<b>1627.13</b>	<b>1254.72</b>	<b>2895.91</b>	<b>5097.43</b>
2	<b>Segment Results (Profit) (+)/ Loss (-) before tax and Interest</b>						
	Pharma Division	-181.63	-73.21	165.37	-254.86	240.34	466.66
	Real Estate Division	193.24	-38.22	50.31	155.00	38.64	25.57
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total</b>	<b>11.61</b>	<b>-111.44</b>	<b>215.69</b>	<b>-99.86</b>	<b>278.99</b>	<b>492.23</b>
	Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.01	0.00	0.13	0.16
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Profit Before Tax</b>	<b>11.61</b>	<b>-111.44</b>	<b>215.67</b>	<b>-99.86</b>	<b>278.86</b>	<b>492.07</b>
3	<b>Capital Employed</b>						
	<b>Segment Assets (A)</b>						
	Pharma Division	6175.63	6573.04	12727.61	6175.63	12727.61	12434.15
	Real Estate Division	6391.29	6157.87	169.10	6391.29	169.10	164.48
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total (A)</b>	<b>12566.93</b>	<b>12730.92</b>	<b>12896.71</b>	<b>12566.92</b>	<b>12896.71</b>	<b>12598.64</b>
	<b>Segment Liabilities (B)</b>						
	Pharma Division	525.80	820.30	1019.36	525.80	1019.36	741.50
	Real Estate Division	55.59	55.12	0.00	55.59	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total (B)</b>	<b>581.38</b>	<b>875.42</b>	<b>1019.36</b>	<b>581.38</b>	<b>1019.36</b>	<b>741.50</b>
4	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>						
	Pharma Division	5649.83	5752.75	11708.25	5649.83	11708.24	11692.66
	Real Estate Division	6335.70	6102.76	169.10	6335.70	169.10	164.48
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>11985.53</b>	<b>11855.50</b>	<b>11877.34</b>	<b>11985.53</b>	<b>11877.34</b>	<b>11857.14</b>

DATE: 08.11.2023  
PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED

  
ALOK K GARG  
MANAGING DIRECTOR  
DIN: 00274321

**NOTES:**

1. The above unaudited results for the Quarter and half year ended Sept. 30, 2023 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 08, 2023. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and will also be available on the websites of the Stock exchange i.e. [www.bseindia.com](http://www.bseindia.com) for the benefit of shareholders and investors.
7. During the quarter the company has started the sale of the shops in MEDICAPS BUSINESS PARK" and generated the revenue of Rs. 210.64 Lacs from real estate division after discounting of pharma business.

DATE : 08/11/2023  
PLACE: INDORE

For and on behalf of the Board of directors of  
MEDI-CAPS LIMITED

  
**A L O K K G A R G**  
MANAGING DIRECTOR  
DIN: 00274321